Relmada Therapeutics

Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs See more here

Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety See more here

Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development See more here

Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as executive Vice President, Head of Research and Development See more here

Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer See more here

Relmada Therapeutics Strengthens Board of Directors with Appointment of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool See more here

Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares See more here

Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression Findings show that REL-1017 has rapid onset and sustained antidepressant efficacy with statistically significant differences compared to placebo on all efficacy measures See more here

Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression REL-1017 is a novel NMDA receptor antagonist in development as a rapidly acting oral agent for the treatment of depression  See more here

Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results Research Findings Accepted for Publication in Journal of Clinical Psychopharmacology   See more here